glp 1 linked to blindness sudden Recent studies have begun explore a possible link between GLP-1 GLP-1 drugs may be linked

Sobo offers a more complete approach to medical weight loss, peptide therapy, and metabolic health

Akinola O, Gabriel M, Suleiman A-A, Olorunsogbon F

In this study, with a median follow-up of 25 months, the primary composite end point including cardiovascular death, MI, stroke, and hospitalization for unstable angina occurred in 406 patients (13.4%) in the lixisenatide group and in 399 (13.2%) in the placebo group (HR, 1.02

Martin Whyte, an associate professor of metabolic medicine at the University of Surrey, explains one possible theory as to why people tend to regain weight after they stop these medications

I have had no side effects, and I cant wait to start month 2